ViaDerma, Inc. News

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More

LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is very pleased to announce several exciting business updates for current and prospective shareholders, partners, and h

GlobeNewswireJul 6, 2023 08:00 ET

ViaDerma, Inc. (OTCMKTS:VDRM) Short Interest Update

ViaDerma, Inc. (OTCMKTS:VDRM – Get Rating) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 48,900 shares, a d

Defense WorldMar 28, 2023 04:44 ET

ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and we expect this process to be completed within a few weeks.

GlobeNewswireMar 16, 2023 08:09 ET

ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

The global hair restoration market is expected to reach $13.6 billion by 2028LOS ANGELES, March 08, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce their plans to lau

GlobeNewswireMar 8, 2023 08:05 ET

ViaDerma Provides an Update on Current & Future Business Activities

The Company has expanded its current wound care licensing agreement to 11 states and expects to be nationwide within the next 12 monthsLOS ANGELES, March 02, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc.

GlobeNewswireMar 2, 2023 08:08 ET

ViaDerma, Inc. (OTCMKTS:VDRM) Sees Significant Increase in Short Interest

ViaDerma, Inc. (OTCMKTS:VDRM – Get Rating) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 745,000 shares, an

Defense WorldMar 2, 2023 04:03 ET

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

INTENT SCIENCES has a proven track record of achieving exceptional outcomes with growing businesses of all types & sizes.LOS ANGELES, Jan. 12, 2023 (GLOBE NEWSWIRE) --  ViaDerma, Inc., (OTC Pink: VD

GlobeNewswireJan 12, 2023 08:05 ET

ViaDerma, Inc. (OTCMKTS:VDRM) Short Interest Down 70.0% in October

ViaDerma, Inc. (OTCMKTS:VDRM – Get Rating) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 15,000 shares, a drop of 70.0% from the September 30t

Financial News LiveOct 27, 2022 10:14 ET

ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year

Revenues increased by over 4000% in 2021, while liabilities decreased by more than 25%LOS ANGELES, March 31, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., ("Company") (OTC Pink: VDRM) announces the relea

GlobeNewswireMar 31, 2022 05:07 ET

ViaDerma intends to offer two new improved versions of its flagship product, Vitastem and Vitastem Ultra

ViaDerma (OTCPK:VDRM) plans to offer two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra.The original Vitastem is an FDA-registered drug and one of the world's stron

Seeking AlphaOct 4, 2021 07:06 ET